SBRT在生存和癌症控制方面与早期肺癌的手术相匹配,其副作用减少,生活质量提高。 SBRT matches surgery in survival and cancer control for early lung cancer, with fewer side effects and better quality of life.

一项长达十年的研究发现,立体体体辐射治疗(SBRT)的存活率与早期非小型细胞肺癌手术的存活率相当,SBRT的10年总体存活率为69%,外科为66%。 A decade-long study finds stereotactic body radiation therapy (SBRT) offers survival rates comparable to surgery for early-stage non-small cell lung cancer, with 10-year overall survival at 69% for SBRT and 66% for surgery. 该研究涉及每组80名病人,显示类似的癌症控制、减少副作用、提高SBRT的生活质量,使由于年龄或健康问题无法接受外科手术的病人成为可行的非侵扰性选择。 The research, involving 80 patients in each group, shows similar cancer control, fewer side effects, and better quality of life with SBRT, making it a viable non-invasive option for patients who can’t undergo surgery due to age or health issues.